BPG is committed to discovery and dissemination of knowledge
Featured Articles
12/12/2024 12:06:17 PM | Browse: 241 | Download: 762
 |
Received |
|
2024-08-21 03:09 |
|
Peer-Review Started |
|
2024-05-01 06:16 |
|
First Decision by Editorial Office Director |
|
2024-09-16 05:52 |
|
Return for Revision |
|
2024-09-16 16:50 |
|
Revised |
|
2024-10-16 02:42 |
|
Publication Fee Transferred |
|
2024-11-08 08:08 |
|
Second Decision by Editor |
|
2024-11-05 02:41 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-11-05 07:42 |
|
Articles in Press |
|
2024-11-05 07:42 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-11-21 03:40 |
|
Publish the Manuscript Online |
|
2024-12-12 09:30 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Transarterial chemoembolization combined with lenvatinib and sintilimab vs lenvatinib alone in intermediate-advanced hepatocellular carcinoma
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Fei-Da Wu, Hai-Feng Zhou, Wei Yang, Di Zhu, Bi-Fei Wu, Hai-Bin Shi, Sheng Liu and Wei-Zhong Zhou |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Wei-Zhong Zhou, MD, PhD, Department of Interventional Radiology, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Gulou District, Nanjing 210029, Jiangsu Province, China. xmjbq007@163.com |
| Key Words |
Hepatocellular carcinoma; Transarterial chemoembolization; Sintilimab; Lenvatinib; Immunotherapy; Programmed cell death 1; Prognosis |
| Core Tip |
This study evaluates the efficacy and safety of combining transarterial chemoembolization (TACE) with lenvatinib and sintilimab compared to TACE with lenvatinib alone in patients with intermediate-advanced hepatocellular carcinoma. The results indicate that TACE with lenvatinib and sintilimab significantly improves overall survival (22.4 months vs 14.1 months) and progression-free survival (14.1 months vs 9.6 months), with a higher objective response rate (70% vs 55.6%). Notably, no severe adverse events were reported, suggesting that the combination therapy is effective and safe. These findings support the inclusion of sintilimab in hepatocellular carcinoma treatment regimens. |
| Publish Date |
2024-12-12 09:30 |
| Citation |
Wu FD, Zhou HF, Yang W, Zhu D, Wu BF, Shi HB, Liu S, Zhou WZ. Transarterial chemoembolization combined with lenvatinib and sintilimab vs lenvatinib alone in intermediate-advanced hepatocellular carcinoma. World J Gastrointest Oncol 2025; 17(1): 96267 |
| URL |
https://www.wjgnet.com/1948-5204/full/v17/i1/96267.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v17.i1.96267 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
